Form 4: Aytu BioPharma Executive Greg Pyszczymuka Acquires 7,000 Employee Stock Options

Chief Commercial Officer Greg Pyszczymuka acquired 7,000 employee stock options in Aytu BioPharma, Inc. on November 6, 2024.

Summary

• Greg Pyszczymuka, Chief Commercial Officer of Aytu BioPharma, Inc., acquired 7,000 employee stock options on November 6, 2024.
• The exercise price of these options is $1.84.
• The options vest in installments, starting with 1/3 on November 6, 2025, and the remainder in 24 equal monthly installments beginning December 6, 2025.
• The options expire on November 6, 2034.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it indicates executive alignment with company performance.

Positives

• The acquisition of stock options by a key executive could signal confidence in the company's future performance.

Industry Context

This is a standard practice for incentivizing executives in publicly traded companies. Stock options align the executive's interests with those of the shareholders.

Comparison to Industry Standards

• Granting stock options to executives is a common practice across the pharmaceutical and biotechnology industries.
• Companies like Pfizer, Amgen, and Johnson & Johnson routinely use stock options as part of their executive compensation packages.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.

Stakeholder Impact

• The granting of stock options can potentially align the interests of management with those of shareholders, encouraging decisions that increase shareholder value.

Key Dates

Keywords

Aytu BioPharma, Stock Options, Form 4, Executive Compensation, Greg Pyszczymuka, AYTU